TY - JOUR
T1 - Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014
AU - Chen, Sharon C A
AU - Sorrell, Tania Christine
AU - Chang, Christina Catherine
AU - Paige, Emma
AU - Bryant, Penelope A
AU - Slavin, Monica Anne
PY - 2014
Y1 - 2014
N2 - Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the Candida spp., Cryptococcus spp., Pneumocystis jirovecii and some lesser-known pathogens. Candida species remain the most common cause of invasive yeast infections (and the most common human pathogenic fungi). These guidelines present evidence-based recommendations for the antifungal management of established, invasive yeast infections in adult and paediatric patients in the haematology/oncology setting. Consideration is also given to the critically ill patient in intensive care units, including the neonatal intensive care unit. Evidence for pre-emptive or diagnostic-driven antifungal therapy is also discussed. For the purposes of this paper, invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections. Specific recommendations for the management of Pneumocystis jirovecii are presented in an accompanying article (see consensus guidelines by Cooley etal. appearing elsewhere in this supplement).
AB - Pathogenic yeast forms are commonly associated with invasive fungal disease in the immunocompromised host, including patients with haematological malignancies and patients of haemopoietic stem cell transplants. Yeasts include the Candida spp., Cryptococcus spp., Pneumocystis jirovecii and some lesser-known pathogens. Candida species remain the most common cause of invasive yeast infections (and the most common human pathogenic fungi). These guidelines present evidence-based recommendations for the antifungal management of established, invasive yeast infections in adult and paediatric patients in the haematology/oncology setting. Consideration is also given to the critically ill patient in intensive care units, including the neonatal intensive care unit. Evidence for pre-emptive or diagnostic-driven antifungal therapy is also discussed. For the purposes of this paper, invasive yeast diseases are categorised under the headings of invasive candidiasis, cryptococcosis and uncommon yeast infections. Specific recommendations for the management of Pneumocystis jirovecii are presented in an accompanying article (see consensus guidelines by Cooley etal. appearing elsewhere in this supplement).
UR - http://onlinelibrary.wiley.com/doi/10.1111/imj.12597/pdf
U2 - 10.1111/imj.12597
DO - 10.1111/imj.12597
M3 - Article
SN - 1444-0903
VL - 44
SP - 1315
EP - 1332
JO - Internal Medicine Journal
JF - Internal Medicine Journal
IS - 12
ER -